10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Hepatocellular Carcinoma
5 articles
EMERALD-1 Trial: Immunotherapy Combo Boosts Survival in Liver Cancer
Adding durvalumab and bevacizumab to TACE improves progression-free survival in hepatocellular carcinoma.
Unmasking the Risk Factors: New Insights into Immune-Mediated Hepatotoxicity in Cancer Immunotherapy
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
Doxorubicin Addition to Sorafenib Fails to Improve Survival in Advanced Liver Cancer
Phase III trial shows doxorubicin plus sorafenib no better than sorafenib alone for advanced HCC.
ATRA Boosts FOLFOX4 Efficacy in Advanced Liver Cancer with Metastasis
Study shows FOLFOX4 + ATRA improves survival in advanced hepatocellular carcinoma with metastasis
New Hope for Liver Cancer: Tislelizumab Shows Promise as First-Line Treatment
Study finds tislelizumab comparable to sorafenib for unresectable hepatocellular carcinoma treatment